Overview Financials News + Filings Key Docs Ownership
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
|
|
AC Immune SA (ACIU)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 04/28/2023 |
6-K
| Quarterly results |
| 07/28/2022 |
6-K
| Quarterly results |
| 04/28/2022 |
6-K
| Quarterly results |
| 11/08/2021 |
6-K
| Quarterly results |
| 08/04/2021 |
6-K
| Quarterly results |
| 04/28/2021 |
6-K
| Quarterly results |
| 11/13/2020 |
6-K
| Quarterly results |
| 08/05/2020 |
6-K
| Quarterly results |
| 05/04/2020 |
6-K
| Quarterly results |
| 08/14/2019 |
6-K
| Quarterly results |
| 05/15/2019 |
6-K
| Quarterly results|
Docs:
|
"FORM 6-K",
"Interim Condensed Financial Statements (Unaudited) (IFRS) as of and for the Three Months Ended March 31, 2019",
"Management’ s Discussion and Analysis of Financial Condition and Results of Operations",
"AC Immune Reports Q1 2019 Financial Results and Business Update Lausanne, Switzerland, May 15, 2019 – AC Immune SA , a Swiss-based, biopharmaceutical company with a broad clinical-stage pipeline focused on pioneering Precision Medicine in neurodegenerative diseases, today announced financial results for the first quarter ended March 31, 2019. Prof. Andrea Pfeifer, Ph.D., CEO of AC Immune, commented: “Our CHF 300 million cash position, funds operations through Q3 2023, allowing us to achieve multiple potentially transformative goals. This is thanks to SupraAntigen TM and Morphomer TM , our proprietary discovery platforms, which already have generated multiple clinical and preclinical product-candidates and about CHF 300 million in partnering revenues for rights to our industry-leading thera..." |
|
| 11/13/2017 |
6-K
| Quarterly results|
Docs:
|
"FORM 6-K",
"Interim Condensed Financial Statements (Unaudited) (IFRS) as of and for the Three and Nine Months Ended September 30, 2017",
"Management’ s Discussion and Analysis of Financial Condition and Results of Operations",
"AC Immune Reports Third Quarter 2017 Financial Results and Corporate Update § Expansion of pipeline with two new antibodies against proteins alpha-synuclein and TDP-43 § Recruitment of first cohort completed for anti-beta vaccine targeting Alzheimer’ s symptoms in adults with Down syndrome § Strong cash position of CHF 117.2 million provides resources to advance pipeline of nine therapeutic and three diagnostic candidates Lausanne, Switzerland, November 13, 2017 – AC Immune SA , a Swiss-based, clinical stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced financial results for the third-quarter ended September 30, 2017. Prof. Andrea Pfeifer, CEO of AC Immune, commented: “Our third quarter was highlighted by our pipeline ..." |
|
| 08/09/2017 |
6-K
| Quarterly results|
Docs:
|
"FORM 6-K",
"Interim Condensed Financial Statements (Unaudited) (IFRS) as of and for the Three and Six Months Ended June 30, 2017",
"Management’ s Discussion and Analysis of Financial Condition and Results of Operations",
"AC IMMUNE REPORTS second QuArter 2017 financial results § Strong cash position of CHF 124.2 million provides resources to advance pipeline of seven therapeutic and three diagnostic candidates § Increased R&D investment across three pillars of Alzheimer`s disease, neuro-orphan indications and diagnostics § Entered into first Asian collaboration for neurodegenerative diseases and neuroinflammation with Essex Bio-Technology Lausanne, Switzerland, August 9, 2017 – AC Immune SA , a Swiss-based, clinical stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced financial results for the second quarter ended June 30, 2017. Prof. Andrea Pfeifer, CEO of AC Immune, commented: “Our second quarter was highlighted by the exciting agreeme..." |
|
| 05/11/2017 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] |
| 11/14/2016 |
6-K
| Quarterly results |
|
|